Rifaximin Is Effective for the Treatment of Clostridium difficile—Associated Diarrhea: Results of an Open-Label Pilot Study

Table 2

CDAD symptom improvement with rifaximin 1200 mg/day for 10 days.

Patient	Symptom resolution with rifaximin	TLUS, h*	Followup stool EIA^†	Relapse at 2 weeks	Relapse (followup, d)
(1)	Yes	84	NA^‡	No	No (261)
(2)	Yes^‡	282	Positive	Yes	NA
(3)	Yes	128	Negative	No	No (194)
(4)	Yes	108	Negative	No	Yes (52)
(5)	Yes	187	Negative	No	No (162)
(6)	Yes	96	Positive	No	No (149)
(7)	Yes	192	Negative	No	No (160)
(8)	Yes	131	Negative	No	No (36)

CDAD: Clostridium difficile-associated diarrhea; EIA: enzyme immunoassay; NA: not applicable; TLUS: time to last unformed stool.
*From ingestion of first rifaximin tablet. ^†Obtained on day 10 following initiation of rifaximin therapy. ^‡Followup stool sample not provided. ^‡Symptom resolution occurred 2 days after completing the 10-day course of therapy.